Brief: Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses
13/03/2025 12:10
March 13 (Reuters) - Polyrizon Ltd PLRZ.O: POLYRIZON LAUNCHES PRECLINICAL STUDIES FOR INTRANASAL NALOXONE TO COMBAT OPIOID OVERDOSE USING CUTTING-EDGE PLATFORM Source text: ID:nGNX9cVj3R Further company coverage: PLRZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polyrizon
See all newsBrief: Polyrizon Files For U.S. Patent Application To Expand Ip Moat Around Intranasal Drug-Delivery Platform
Brief: Polyrizon Advances Towards Human Clinical Trials Secures First U.S. Clinical Site For Nasarix™ Allergy Blocker Clinical Trial
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:58 AM
Enters Agreements For Registered Direct Offering Of Ordinary Shares And Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America